Further studies are required to reveal whether targeting of the CD163-TWEAK pathway might be a potential strategy for treating vascular disease and/or skin fibrosis in SSc. Arthritis Research & Therapy, June 24 2013, 15:R69. (Also see: Research on Digital Ulcers)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.